LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 2 | E24 | 72 | hr | 2543 | 4660 | 5761 | 0.8088 | 0.6708 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 3 | E24 | 72 | hr | 2543 | 4957 | 5760 | 0.8605 | 0.7607 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 1 | E23 | 72 | hr | 2543 | 4501 | 5734 | 0.7849 | 0.6269 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 2 | E23 | 72 | hr | 2543 | 4355 | 5761 | 0.7559 | 0.5776 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 3 | E23 | 72 | hr | 2543 | 4709 | 5760 | 0.8174 | 0.6858 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 1 | E22 | 72 | hr | 2543 | 4277 | 5734 | 0.7458 | 0.5576 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 2 | E22 | 72 | hr | 2543 | 3998 | 5761 | 0.6939 | 0.4673 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 3 | E22 | 72 | hr | 2543 | 4665 | 5760 | 0.8098 | 0.6724 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 2543 | 4043 | 5734 | 0.7050 | 0.4846 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 2543 | 3927 | 5761 | 0.6816 | 0.4451 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 2543 | 4658 | 5760 | 0.8086 | 0.6703 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 1 | E20 | 72 | hr | 2543 | 3481 | 5734 | 0.6070 | 0.3068 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 2 | E20 | 72 | hr | 2543 | 3234 | 5761 | 0.5613 | 0.2258 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 3 | E20 | 72 | hr | 2543 | 3719 | 5760 | 0.6456 | 0.3800 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 1 | E19 | 72 | hr | 2543 | 2891 | 5734 | 0.5041 | 0.1154 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 2 | E19 | 72 | hr | 2543 | 2695 | 5761 | 0.4678 | 0.0503 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 3 | E19 | 72 | hr | 2543 | 3094 | 5760 | 0.5371 | 0.1807 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 1 | F24 | 72 | hr | 2543 | 4091 | 5734 | 0.7134 | 0.4996 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 2 | F24 | 72 | hr | 2543 | 4073 | 5761 | 0.7069 | 0.4906 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 3 | F24 | 72 | hr | 2543 | 4768 | 5760 | 0.8277 | 0.7037 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 1 | F23 | 72 | hr | 2543 | 4325 | 5734 | 0.7542 | 0.5725 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 2 | F23 | 72 | hr | 2543 | 4215 | 5761 | 0.7316 | 0.5345 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 3 | F23 | 72 | hr | 2543 | 4421 | 5760 | 0.7674 | 0.5979 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 1 | F22 | 72 | hr | 2543 | 4162 | 5734 | 0.7258 | 0.5218 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 2 | F22 | 72 | hr | 2543 | 4087 | 5761 | 0.7094 | 0.4949 |